Table 2.

Initial disclosure dates of targeted therapy trials in intrahepatic cholangiocarcinoma

Inhibitor	Target	Disclosure date	Design	Results	Reference
Infigratinib (QED)	FGFR2	1/2018	PhII n = 61	ORR 15%, PFS 5.8 mo	[41]
Futibatinib (Taiho)	FGFR2	6/2018	PhI n = 45	ORR 25%	[42]
Pemigatinib (Incyte)	FGFR2	10/2018	PhII n = 47	ORR 24%, PFS 6.8 mo	[43]
Dabrafenib + trametinib (Novartis)	BRAF	1/2019	PhII n = 33	ORR 41%, PFS 7.2 mo	[44]
Derazantinib (Basilea)	FGFR2	1/2019	PhI/II n = 29	ORR 21%, PFS 5.7 mo	[45]
Debio 1347 (Debiopharm)	FGFR2	3/2019	PhI n = 9	ORR 22%	[46]
Neratinib (Puma)	HER2	7/2019	PhII n = 19	ORR 11%, PFS 1.8 mo	[27]
Erdafitinib (Janssen)	FGFR2	8/2019	PhI n = 11	ORR 27%	[47]
Ivosidenib (Agios)	IDH1	9/2019	PhIII n = 185	ORR 2.4%, PFS 2.7 mo	[48]

Abbreviations: ORR, overall response rate; PFS, progression‐free survival; PhI, phase I; PhII, phase II; PhIII, phase III.